trial · primary record
Keynatinib
Lymphoma, B-Cell
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 75 |
| Primary completion | 2033-04-10 |
| Primary endpoint | Objective Response Rate (CR+PR) |
| Registry ID | NCT04807881 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:49.573Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04807881
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.